STAT3 and Duchenne muscular dystrophy: Based on the premise that PTPN1 and STAT3 signaling are dysregulated in DMD MuSCs, we used K884, a novel PTPN1/2 inhibitor, to alleviate the negative repression on STAT3 activation in DMD MuSCs.